5-Alpha Reductase Inhibitor Use and Prostate Cancer Prevention: A Victim of the Times?

    Robert J. Hamilton
    Studysummary This commentary discusses how recent shifts in prostate cancer screening and management may render 5-alpha reductase inhibitors irrelevant for chemoprevention, despite evidence of their long-term safety and effectiveness in preventing low-grade prostate cancer.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on aacrjournals.org →
    Discuss this study in the Community →

    Research cited in this study 1

    1. The Risks and Benefits of 5α-Reductase Inhibitors for Prostate Cancer Prevention New England journal of medicine/˜The œNew England journal of medicine · 2011